Skip header and navigation

Refine By

381 records – page 1 of 39.

A 1-year randomized study to evaluate the effects of a dose reduction in oral contraceptives on lipids and carbohydrate metabolism: 20 microg ethinyl estradiol combined with 100 microg levonorgestrel.

https://arctichealth.org/en/permalink/ahliterature176202
Source
Contraception. 2005 Feb;71(2):111-7
Publication Type
Article
Date
Feb-2005
Author
Sven O Skouby
Jan Endrikat
Bernd Düsterberg
Werner Schmidt
Christoph Gerlinger
Jens Wessel
Henri Goldstein
Joergen Jespersen
Author Affiliation
Department of Obstetrics and Gynecology, Frederiksberg Hospital, University of Copenhagen, DK 2000 Copenhagen F, Denmark. sven.skouby@fh.hosp.dk
Source
Contraception. 2005 Feb;71(2):111-7
Date
Feb-2005
Language
English
Publication Type
Article
Keywords
Adult
Blood Glucose - metabolism
C-Peptide - blood
Carbohydrate Metabolism - drug effects
Cholesterol, HDL - blood
Cholesterol, LDL - blood
Contraceptive Agents, Female - administration & dosage - pharmacology
Contraceptives, Oral, Combined - administration & dosage - pharmacology
Denmark
Dose-Response Relationship, Drug
Ethinyl Estradiol - administration & dosage - pharmacology
Fatty Acids, Nonesterified - blood
Female
Humans
Insulin - blood
Levonorgestrel - administration & dosage - pharmacology
Lipid Metabolism - drug effects
Prospective Studies
Time Factors
Treatment Outcome
Triglycerides - blood
Abstract
To evaluate the impact on lipid and carbohydrate variables of a combined one-third ethinyl estradiol (EE)/levonorgestrel (LNG) dose reduction in oral contraceptives.
In an open-label, randomized study, a dose-reduced oral contraceptive containing 20 microg EE and 100 microg LNG (20 EE/100 LNG) was compared with a reference preparation containing 30 microg EE and 150 microg LNG (30 EE/150 LNG). One-year data from 48 volunteers were obtained.
We found a decrease of HDL2 cholesterol and increases of low-density lipoprotein cholesterol, very low-density lipoprotein cholesterol and total triglycerides in both treatment groups from baseline to the 13th treatment cycle. Although for four of six variables, the changes in the 20 EE group were lower compared with the 30 EE group, none of the differences between the two treatments were statistically significant. The median values for the fasting levels of insulin, C-peptide and free fatty acids slightly increased or remained unchanged while the fasting glucose levels slightly decreased after 13 treatment cycles. While the glucose area under the curve (AUC) (0-3 h) was similar in both groups during the OGTT, the insulin AUC(0-3 h) was less increased in the 20 EE/100 LNG group compared with the 30 EE/150 LNG group. None of the differences between the treatment groups for any of the carbohydrate metabolism variables were statistically significant at any time point. Both study treatments were safe and well tolerated by the volunteers.
Similar effects on the lipid and carbohydrate profiles were found for both preparations. The balanced one-third EE dose reduction in this new oral contraceptive caused slightly lower, but insignificant, changes in the lipid and carbohydrate variables compared with the reference treatment.
PubMed ID
15707560 View in PubMed
Less detail

The 21-year follow-up of the Cardiovascular Risk in Young Finns Study: risk factor levels, secular trends and east-west difference.

https://arctichealth.org/en/permalink/ahliterature180902
Source
J Intern Med. 2004 Apr;255(4):457-68
Publication Type
Article
Date
Apr-2004
Author
M. Juonala
J S A Viikari
N. Hutri-Kähönen
M. Pietikäinen
E. Jokinen
L. Taittonen
J. Marniemi
T. Rönnemaa
O T Raitakari
Author Affiliation
The Centre of Applied and Preventive Cardiovascular Medicine, University of Turku, Turku, Finland.
Source
J Intern Med. 2004 Apr;255(4):457-68
Date
Apr-2004
Language
English
Publication Type
Article
Keywords
Adult
Blood Pressure - physiology
Body mass index
Cardiovascular Diseases - blood - epidemiology
Cholesterol - blood
Cholesterol, HDL - blood
Cholesterol, LDL - blood
Female
Finland - epidemiology
Follow-Up Studies
Humans
Male
Patient Dropouts
Risk factors
Smoking - adverse effects
Triglycerides - blood
Abstract
The Cardiovascular Risk in Young Finns Study is an on-going multicentre study of atherosclerosis precursors in Finnish children and young adults. We have collected risk factor data in the 21-year follow-up performed in 2001. The aims of this analysis were to examine the levels, secular trends and east-west difference in risk factors amongst young adults.
Population based follow-up study.
A total of 2283 participants aged 24-39 years in 2001 (63.5% of the original cohort).
Levels of serum lipids, apolipoproteins, blood pressure and smoking.
The mean serum total cholesterol, low density lipoprotein cholesterol, high density lipoprotein (HDL) cholesterol and triglyceride concentrations in 24-39-year-old adults were 5.16, 3.27, 1.29 and 1.34 mmol L(-1), respectively. Total cholesterol (5.21 vs. 5.12 mmol L(-1), P = 0.046), HDL cholesterol (1.31 vs. 1.28 mmol L(-1), P = 0.027), systolic blood pressure (118 vs. 115 mmHg, P
PubMed ID
15049880 View in PubMed
Less detail

The 2003 Canadian recommendations for dyslipidemia management: revisions are needed.

https://arctichealth.org/en/permalink/ahliterature175311
Source
CMAJ. 2005 Apr 12;172(8):1027-31
Publication Type
Article
Date
Apr-12-2005
Author
Douglas G Manuel
Peter Tanuseputro
Cameron A Mustard
Susan E Schultz
Geoffrey M Anderson
Sten Ardal
David A Alter
Andreas Laupacis
Author Affiliation
Institute for Clinical Evaluative Sciences, Toronto, Ont. doug.manuel@ices.on.ca
Source
CMAJ. 2005 Apr 12;172(8):1027-31
Date
Apr-12-2005
Language
English
Publication Type
Article
Keywords
Adolescent
Adult
Aged
Canada
Cholesterol, LDL - blood
Coronary Disease - mortality - prevention & control
Cost-Benefit Analysis
Health Expenditures
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use
Hyperlipidemias - drug therapy
Hypolipidemic Agents - therapeutic use
Middle Aged
Practice Guidelines as Topic
Risk factors
Notes
Cites: Eur Heart J. 2003 Sep;24(17):1601-1012964575
Cites: CMAJ. 2003 Jun 24;168(13):1644-5; author reply 1645-612821610
Cites: Can J Cardiol. 2003 Nov;19(12):1359-6614631469
Cites: Can J Cardiol. 2003 Dec;19(13):1499-50214760440
Cites: Am J Med. 2004 Apr 15;116(8):540-515063816
Cites: JAMA. 2004 Apr 21;291(15):1864-7015100205
Cites: Am Heart J. 1991 Jan;121(1 Pt 2):293-81985385
Cites: N Engl J Med. 1998 Nov 5;339(19):1349-579841303
Cites: Can J Cardiol. 1999 Apr;15(4):445-5110322254
Cites: CMAJ. 2003 Oct 28;169(9):921-414581310
Cites: Fam Pract. 2003 Feb;20(1):16-2112509365
Cites: JAMA. 2002 Jul 24-31;288(4):462-712132976
Cites: JAMA. 2002 Jul 24-31;288(4):455-6112132975
Cites: JAMA. 1999 Dec 22-29;282(24):2340-610612322
Cites: CMAJ. 2000 May 16;162(10):1441-710834048
Cites: CMAJ. 2000 Aug 22;163(4):403-810976255
Cites: Lancet. 2002 Jul 6;360(9326):7-2212114036
Comment In: CMAJ. 2005 Nov 8;173(10):1210; author reply 121016275979
Comment In: CMAJ. 2005 Nov 8;173(10):1207; author reply 121016275976
Comment In: CMAJ. 2005 Apr 12;172(8):1033-4; discussion 103715824410
Erratum In: CMAJ. 2005 Jul 19;173(2):133
PubMed ID
15824409 View in PubMed
Less detail

Achieving cholesterol targets by individualizing starting doses of statin according to baseline low-density lipoprotein cholesterol and coronary artery disease risk category: the CANadians Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration (CanACTFAST) study.

https://arctichealth.org/en/permalink/ahliterature145456
Source
Can J Cardiol. 2010 Feb;26(2):80-6
Publication Type
Article
Date
Feb-2010
Author
Ehud Ur
Anatoly Langer
Simon W Rabkin
Cristina-Dana Calciu
Lawrence A Leiter
Author Affiliation
University of British Columbia, Vancouver, BC, Canada.
Source
Can J Cardiol. 2010 Feb;26(2):80-6
Date
Feb-2010
Language
English
Publication Type
Article
Keywords
Adult
Aged
Canada
Cholesterol, LDL - blood - drug effects
Coronary Artery Disease - blood - etiology - prevention & control
Dose-Response Relationship, Drug
Female
Follow-Up Studies
Heptanoic Acids - administration & dosage
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage
Hypercholesterolemia - blood - complications - drug therapy
Male
Middle Aged
Pyrroles - administration & dosage
Risk factors
Treatment Outcome
Abstract
Despite an increasing body of evidence on the benefit of lowering elevated levels of low-density lipoprotein cholesterol (LDL-C), there is still considerable concern that patients are not achieving target LDL-C levels.
The CANadians Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration (CanACTFAST) trial tested whether an algorithm-based statin dosing approach would enable patients to achieve LDL-C and total cholesterol/high-density lipoprotein cholesterol (TC/HDL-C) ratio targets quickly.
Subjects requiring statin therapy, but with an LDL-C level of 5.7 mmol/L or lower, and triglycerides of 6.8 mmol/L or lower at screening participated in the 12-week study, which had two open-label, six-week phases: a treatment period during which patients received 10 mg, 20 mg, 40 mg or 80 mg of atorvastatin based on an algorithm incorporating baseline LDL-C value and cardiovascular risk; and patients who achieved both LDL-C and TC/HDL-C ratio targets at six weeks continued on the same atorvastatin dose. Patients who did not achieve both targets received dose uptitration using a single-step titration regimen. The primary efficacy outcome was the proportion of patients achieving target LDL-C levels after 12 weeks.
Of 2016 subjects screened at 88 Canadian sites, 1258 were assigned to a study drug (1101 were statin-free and 157 were statin-treated at baseline). The proportion of subjects who achieved LDL-C targets after 12 weeks of treatment was 86% (95% CI 84% to 88%) for statin-free patients and 54% (95% CI 46% to 61%) for statin-treated patients. Overall, 1003 subjects (80%; 95% CI 78% to 82%) achieved both lipid targets.
Algorithm-based statin dosing enables patients to achieve LDL-C and TC/HDL-C ratio targets quickly, with either no titration or a single titration.
Notes
Cites: CMAJ. 2000 May 16;162(10):1441-710834048
Cites: Atherosclerosis. 2007 Mar;191(1):135-4616643923
Cites: JAMA. 2001 May 16;285(19):2486-9711368702
Cites: Am Heart J. 2001 Jun;141(6):949-5611376309
Cites: Am J Med. 2001 Aug 15;111(3):185-9111530028
Cites: JAMA. 2002 Jul 24-31;288(4):462-712132976
Cites: Am J Cardiol. 2003 Jul 1;92(1):79-8112842255
Cites: CMAJ. 2003 Oct 28;169(9):921-414581310
Cites: JAMA. 2004 Mar 3;291(9):1071-8014996776
Cites: Lancet. 1994 Nov 19;344(8934):1383-97968073
Cites: N Engl J Med. 1996 Oct 3;335(14):1001-98801446
Cites: J Am Coll Cardiol. 1998 Sep;32(3):665-729741509
Cites: Am Heart J. 2004 Dec;148(6):1028-3315632889
Cites: Am Heart J. 2005 Jan;149(1):e115660024
Cites: N Engl J Med. 2005 Apr 7;352(14):1425-3515755765
Cites: Lancet. 2005 Oct 8;366(9493):1267-7816214597
Cites: Can J Cardiol. 2005 Nov;21(13):1187-9316308595
Cites: Am J Cardiol. 2006 Jan 1;97(1):61-716377285
Cites: Am Heart J. 2006 May;151(5):969-7516644313
Cites: Am J Med. 2006 Aug;119(8):676-8316887414
Cites: Can J Cardiol. 2006 Sep;22(11):913-2716971976
Cites: Circulation. 2007 Feb 13;115(6):700-717283260
Cites: Atherosclerosis. 2000 Oct;152(2):489-9610998478
PubMed ID
20151053 View in PubMed
Less detail

Acquired liver fat is a key determinant of serum lipid alterations in healthy monozygotic twins.

https://arctichealth.org/en/permalink/ahliterature113714
Source
Obesity (Silver Spring). 2013 Sep;21(9):1815-22
Publication Type
Article
Date
Sep-2013
Author
S M Kaye
M. Maranghi
L H Bogl
J. Kaprio
A. Hakkarainen
J. Lundbom
N. Lundbom
A. Rissanen
M R Taskinen
K H Pietiläinen
Author Affiliation
Obesity Research Unit, Department of Medicine, Division of Endocrinology, Helsinki University Central Hospital and University of Helsinki, Helsinki, Finland.
Source
Obesity (Silver Spring). 2013 Sep;21(9):1815-22
Date
Sep-2013
Language
English
Publication Type
Article
Keywords
Abdominal Fat
Adult
Apolipoproteins B - blood
Body mass index
Cholesterol - blood
Cholesterol, HDL - blood
Cholesterol, LDL - blood
Exercise
Fatty Liver - blood - complications - genetics - metabolism
Female
Finland
Humans
Liver - metabolism
Male
Multivariate Analysis
Obesity - blood - complications - genetics - metabolism
Subcutaneous Fat
Twins, Monozygotic
Young Adult
Abstract
The effects of acquired obesity on lipid profile and lipoprotein composition in rare BMI-discordant monozygotic (MZ) twin pairs were studied.
Abdominal fat distribution, liver fat (magnetic resonance imaging and spectroscopy), fasting serum lipid profile (ultracentrifugation, gradient gel-electrophoresis, and colorimetric enzymatic methods), and lifestyle factors (questionnaires and diaries) were assessed in 15 BMI-discordant (within-pair difference [?] in BMI >3 kg/m2) and nin concordant (?BMI
PubMed ID
23696329 View in PubMed
Less detail

Age and gender specific serum lipid and apolipoprotein fractiles of Finnish children and young adults. The Cardiovascular Risk in Young Finns Study.

https://arctichealth.org/en/permalink/ahliterature217631
Source
Acta Paediatr. 1994 Aug;83(8):838-48
Publication Type
Article
Date
Aug-1994
Author
K V Porkka
J S Viikari
T. Rönnemaa
J. Marniemi
H K Akerblom
Author Affiliation
Third Department of Medicine, University of Helsinki, Finland.
Source
Acta Paediatr. 1994 Aug;83(8):838-48
Date
Aug-1994
Language
English
Publication Type
Article
Keywords
Adolescent
Adult
Age Factors
Apolipoproteins - blood
Child
Cholesterol, HDL - blood
Cholesterol, LDL - blood
Coronary Disease - blood
Female
Finland
Humans
Lipids - blood
Male
Puberty
Reference Values
Risk factors
Sex Factors
Triglycerides - blood
Abstract
We present fractile data on serum lipids and apolipoproteins A-l and B for children and young adults from the cardiovascular risk in young Finns study cohort of 1986. The sample comprised 2370 fasting children and young adults (1114 males and 1256 females) aged 9, 12, 15, 18, 21 and 24 years. The determinations were performed in duplicate with standard methods. LDL-cholesterol values were calculated. The limits for clearly pathological values (exceeding the 97.5th percentile) irrespective of age and gender were 7.5 mmol/l, 5.0 mmol/l, 3.5 mmol/l and 1.4 g/l for serum total cholesterol, LDL-cholesterol, triglycerides and apolipoprotein B, respectively. Corresponding values (below the 2.5th percentile) for HDL-cholesterol, apolipoprotein A-l, HDL2- and HDL3-cholesterol were 0.80 mmol/l, 1.0 mg/l, 0.20 mmol/l and 0.70 mmol/l, respectively. Approximately 79%, 33% and 7% of males had serum total cholesterol values greater than 4.0 mmol, 5.0 mmol/l and 6.0 mmol/l, respectively. Corresponding percentages for females were 87%, 43% and 10%. However, age-related differences were marked. The prevalence of values, e.g. greater than 6 mmol/l according to age, ranged from 6 to 13% in females and from 3 to 12% in males, emphasizing the need for age-specific reference values. Additionally, postpubertal values for total and LDL-cholesterol tended to be slightly lower compared to prepubertal values, indicating that the reference values for adults do not apply to adolescents and young adults. The age-related changes in lipid levels were evident in each fractile and were especially accentuated in higher fractiles. Fluctuations with age were more pronounced in males than in females. These results are intended to be applied as reference values for diagnosing dyslipidemias.
PubMed ID
7981561 View in PubMed
Less detail

Aggregation of lipoprotein and inflammatory parameters in families with a history of premature myocardial infarction: the Tallinn myocardial infarction study.

https://arctichealth.org/en/permalink/ahliterature154200
Source
Clin Chem Lab Med. 2008;46(11):1602-8
Publication Type
Article
Date
2008
Author
Katrin Aasvee
Elvira Kurvinen
Jouko Sundvall
Matti Jauhiainen
Inna Tur
Author Affiliation
Department of Chronic Disease Prevention, National Institute for Health Development, Tallinn, Estonia. katrin.aasvee@tai.ee
Source
Clin Chem Lab Med. 2008;46(11):1602-8
Date
2008
Language
English
Publication Type
Article
Keywords
Acute-Phase Proteins - metabolism
Adolescent
Adult
Age Factors
Apolipoprotein A-I - blood
Apolipoproteins B - blood
Apolipoproteins E - genetics
C-Reactive Protein - metabolism
Child
Cholesterol - blood
Cholesterol, HDL - blood
Cholesterol, LDL - blood
Family Health
Female
Finland
Humans
Lipoprotein(a) - blood
Lipoproteins - blood
Male
Middle Aged
Myocardial Infarction - blood - genetics
Polymorphism, Genetic
Risk factors
Sex Factors
Triglycerides - blood
Abstract
The offspring of individuals with a history of premature myocardial infarction are at increased risk of premature coronary attacks. The aim of this study was to determine parent/offspring associations of coronary risk factors in families affected by premature myocardial infarction and to compare these to corresponding control families.
The cohort of cases consisted of 71 male survivors of myocardial infarction and their 128 descendants (aged 7-18 years). As control families, 85 randomly selected healthy males with their 66 descendants were investigated. Besides traditional risk factors, serum high sensitive C-reactive protein (hsCRP), apolipoprotein (apo) E phenotypes and lipoprotein(a) were analyzed.
In the offspring of the patients, fibrinogen and atherogenic lipoprotein parameters were higher than in the corresponding controls, but hsCRP, lipoprotein(a) and anthropometric data did not differ between the groups. The adult-offspring positive correlations were detected in fibrinogen and in almost all measured lipoprotein fractions in the affected families; amongst the controls, the association was observed only for triglyceride levels. Multiple logistic regression analysis demonstrated independent association of offspring apoB, apoA-I and fibrinogen levels with a family history of premature myocardial infarction.
The most informative predictors of future coronary attacks during childhood are apoB-100 and apoB/apoA-I ratio; serum hsCRP and lipoprotein(a) do not have predictive value in childhood.
PubMed ID
19012525 View in PubMed
Less detail

Alcohol intake, myocardial infarction, biochemical risk factors, and alcohol dehydrogenase genotypes.

https://arctichealth.org/en/permalink/ahliterature98530
Source
Circ Cardiovasc Genet. 2009 Oct;2(5):507-14
Publication Type
Article
Date
Oct-2009
Author
Janne S Tolstrup
Morten Grønbaek
Børge G Nordestgaard
Author Affiliation
Center for Alcohol Research, National Institute of Public Health, University of Southern Denmark, Copenhagen, Denmark. jst@niph.dk
Source
Circ Cardiovasc Genet. 2009 Oct;2(5):507-14
Date
Oct-2009
Language
English
Publication Type
Article
Keywords
Adult
Aged
Alcohol Dehydrogenase - genetics
Alcohol Drinking - adverse effects
Biological Markers - blood - metabolism
Cholesterol, HDL - blood
Cholesterol, LDL - blood
Denmark - epidemiology
Female
Fibrinogen - metabolism
Follow-Up Studies
Genotype
Humans
Male
Middle Aged
Myocardial Infarction - enzymology - epidemiology - genetics - metabolism
Risk factors
Abstract
BACKGROUND: The risk of myocardial infarction is lower among light-to-moderate alcohol drinkers compared with abstainers. We tested associations between alcohol intake and risk of myocardial infarction and risk factors and whether these associations are modified by variations in alcohol dehydrogenases. METHODS AND RESULTS: We used information on 9584 men and women from the Danish general population in the Copenhagen City Heart Study. During follow-up, from 1991 to 2007, 663 incident cases of myocardial infarction occurred. We observed that increasing alcohol intake was associated with decreasing risk of myocardial infarction, decreasing low-density lipoprotein cholesterol and fibrinogen, increasing diastolic and systolic blood pressure and high-density lipoprotein cholesterol, and with U-shaped nonfasting triglycerides. In contrast, ADH1B and ADH1C genotypes were not associated with risk of myocardial infarction or with any of the cardiovascular biochemical risk factors, and there was no indication that associations between alcohol intake and myocardial infarction and between alcohol intake and risk factors were modified by genotypes. CONCLUSIONS: Increasing alcohol intake is associated with decreasing risk of myocardial infarction, decreasing low-density lipoprotein cholesterol and fibrinogen, increasing diastolic and systolic blood pressure and high-density lipoprotein cholesterol, and U-shaped nonfasting triglycerides. These associations were not modified by ADH1B and ADH1C are genotypes.
PubMed ID
20031627 View in PubMed
Less detail

The analysis by Manuel and colleagues creates controversy with headlines, not data.

https://arctichealth.org/en/permalink/ahliterature175310
Source
CMAJ. 2005 Apr 12;172(8):1033-4; discussion 1037
Publication Type
Article
Date
Apr-12-2005
Author
Jacques Genest
Ruth McPherson
Jiri Frohlich
George Fodor
Author Affiliation
Division of Cardiology, Royal Victoria Hospital, McGill University, Montréal, Que. jacques.genest@muhc.mcgill.ca
Source
CMAJ. 2005 Apr 12;172(8):1033-4; discussion 1037
Date
Apr-12-2005
Language
English
Publication Type
Article
Keywords
Canada
Cholesterol, LDL - blood
Coronary Disease - mortality - prevention & control
Health Expenditures
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use
Hyperlipidemias - drug therapy
Hypolipidemic Agents - therapeutic use
Practice Guidelines as Topic
Risk factors
Notes
Cites: Circulation. 2003 Apr 22;107(15):2059-6512707251
Cites: JAMA. 1999 Dec 22-29;282(24):2340-610612322
Cites: JAMA. 2001 May 16;285(19):2486-9711368702
Cites: Circulation. 2001 Nov 27;104(22):2746-5311723030
Cites: Circulation. 2001 Dec 4;104(23):2855-6411733407
Cites: Lancet. 2002 Jul 6;360(9326):7-2212114036
Cites: CMAJ. 2005 Apr 12;172(8):1027-3115824409
Cites: CMAJ. 2003 Oct 28;169(9):921-414581310
Cites: Can J Public Health. 2004 Jan-Feb;95(1):16-2014768735
Cites: Circulation. 2004 Jul 13;110(2):227-3915249516
Cites: Lancet. 2004 Sep 11-17;364(9438):937-5215364185
Cites: BMJ. 1992 Jul 4;305(6844):15-91638188
Comment On: CMAJ. 2005 Apr 12;172(8):1027-3115824409
PubMed ID
15824410 View in PubMed
Less detail

ANGPTL3 serum concentration and rare genetic variants in Finnish population.

https://arctichealth.org/en/permalink/ahliterature293055
Source
Scand J Clin Lab Invest. 2017 Dec; 77(8):601-609
Publication Type
Journal Article
Date
Dec-2017
Author
Anna Tikka
Jari Metso
Matti Jauhiainen
Author Affiliation
a Genomics and Biomarkers Unit , National Institute for Health and Welfare , Helsinki , Finland.
Source
Scand J Clin Lab Invest. 2017 Dec; 77(8):601-609
Date
Dec-2017
Language
English
Publication Type
Journal Article
Keywords
Adult
Aged
Angiopoietin-like Proteins - blood - genetics
Cholesterol, HDL - blood
Cholesterol, LDL - blood
Cross-Sectional Studies
DNA Mutational Analysis
Female
Finland
Genetic Association Studies
Genetic Predisposition to Disease
Humans
Hypercholesterolemia - blood - genetics
Male
Middle Aged
Mutation
Polymorphism, Single Nucleotide
Risk factors
Abstract
Genetic variants of angiopoietin-like protein 3 (ANGPTL3) are associated with serum triglyceride (TG) and low-density lipoprotein cholesterol (LDL-C) concentration in GWASs. ANGPTL3 deficiency causes declined TG, total cholesterol (TC), LDL-C, high-density lipoprotein cholesterol (HDL-C), apolipoprotein B (apoB) and apolipoprotein A-I (apoA-I) serum concentration, a phenotype defined as familial combined hypolipidaemia (FHBL2). Our aim is to establish whether ANGPTL3 serum protein concentration correlates with lipoproteins and lipids in hyper- or hypolipidaemic subjects, and whether ANGPTL3 sequence variants are associated with untypical lipid profiles. Additionally, 10 subjects with very low lipoprotein concentrations were sequenced for ANGPTL3 for possible loss-of-function (LOF) variants. Study subjects were selected from Finnish FINRISK and Health 2000 surveys. ANGPTL protein concentrations were measured by ELISA method. As a result, ANGPTL3 serum concentration correlated positively with age, phospholipid transfer protein (PLTP) and cholesteryl ester transfer protein (CETP) activities, but not with any of the lipid or lifestyle attributes. No ANGPTL3 variants were found among sequenced samples. Subjects who carried ANGPTL3 sequence variants rs12563308 (n?=?4) and rs199772471 (n?=?1) had abnormally high TC and LDL-C concentrations. Whole exome sequencing data of these five subjects were further analyzed for rare and deleterious missense variants in genes associated with cholesterol metabolism. In conclusion, ANGPTL3 serum protein concentration did not predict lipid concentrations, unlike apolipoprotein C-III (apoC-III) which positively correlated with most of the lipid attributes. ANGPTL3 variant screen yielded five carriers with abnormally high TC concentration; the actual genetic causality, however, could not be verified.
PubMed ID
28972399 View in PubMed
Less detail

381 records – page 1 of 39.